Prognostic Value of 18F-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with Docetaxel

Background and Aim. The availability of new treatments for metastatic castrate-resistant prostate cancer (mCRPC) patients increases the need for reliable biomarkers to help clinicians to choose the better sequence strategy. The aim of the present retrospective and observational work is to investigat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Contrast media and molecular imaging 2019-01, Vol.2019 (2019), p.1-7
Hauptverfasser:	Bernardo, A., Castiglioni, Isabella, Porta, C., Trifirò, G., Vellani, C., Palumbo, R., Baiardi, P., Hodolic, M., Gallivanone, F., Sottotetti, F., D'Ambrosio, Daniela, Quaquarini, E., Canevari, C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomarkers Cancer Cancer therapies Chemotherapy Computed tomography Correlation analysis Decision making Deprivation Drug dosages Emission analysis Fluorine isotopes Medical imaging Medical prognosis Metabolism Metastases Metastasis Nuclear medicine Oncology Parameters Patients Positron emission Positron emission tomography Prostate cancer Regression analysis Statistical analysis Survival Therapy Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!